金属硫蛋白与乳腺癌预后的关系  

CORRELATION BETWEEN METALLOTHIONEIN AND PROGNOSIS IN BREAST CANCER

作　　者：赫杰[1] 胡文庆[1] 杨笔耕[1] 

机构地区：[1]湖北医科大学附属第一医院普外科

出　　处：《中国普外基础与临床杂志》1999年第5期288-289,共2页Chinese Journal of Bases and Clinics In General Surgery

摘　　要：为探讨金属硫蛋白（ Ｍ Ｔ）与乳腺癌转移和预后的关系，应用免疫组织化学 Ｓ Ａ Ｂ Ｃ法检测了乳腺癌及乳腺纤维腺瘤中 Ｍ Ｔ 的表达。结果： Ｍ Ｔ 在乳腺癌、乳腺纤维腺瘤中的表达阳性率分别为 ７３．８％ （６２／８４）和 １５．０％ （３／２０），两者的差异有显著性意义（ Ｐ＜ ０．００５）。 Ｍ Ｔ在乳腺癌中的表达随临床分期的升高而增加。 Ｍ Ｔ 在肿瘤中的表达与手术时腋淋巴结转移无相关性，但在腋淋巴结有转移的肿瘤其 Ｍ Ｔ表达阳性者死亡率高于表达阴性者。 Ｍ Ｔ 在乳腺癌中的超表达与其预后差相关，也与 ５ 年生存率密切相关。本研究结果表明， Ｍ Ｔ 可作为判断乳腺癌预后的指标之一。To investigate the relationship between metallothionein (MT) and prognosis in breast cancer MT expression was determined with immunohistochemical method (SABC). Results: There was a statistically significant association between expression of MT in breast benign and malignant disease ( P <0.005). The positive rate was 73.8%(62/84) and 15.0%(3/20) in breast cancer and mastofibroma respectively. The positivity of MT was stronger in advanced clinical stages than in early clinical stages. There was no association between MT expression and lymph node metastasis. The mortality of the cancer cases with lymph node metastasis having positive MT expression was higher than those with negative MT expression. Conclusion: MT can be taken as a prognostic index of breast cancer.

关 键 词：乳腺癌 金属硫蛋白 免疫组化 预后 

分 类 号：R737.907[医药卫生—肿瘤]